Iron at the cell surface controls DNA synthesis in CCl 39 cells.
Treatment of CCl 39 cells with the impermeable iron II chelator bathophenanthroline disulfonate (BPS) inhibits both DNA synthesis and transplasma membrane electron transport. The inhibition persists when the BPS is removed, and the extract from 10(6) cells contains up to 1.28 nmoles iron II chelated to BPS. The BPS iron II chelate itself is not inhibitory. Both DNA synthesis and electron transport are restored by addition of microM iron II or iron III compounds to extracted cells. Other impermeable chelators for iron II give similar inhibition, whereas the iron III-specific Tiron or copper-specific bathocuproine sulfonate do not inhibit. The inhibition differs from the permeable iron III chelator inhibition of ribonucleotide reductase, because inhibition of DNA synthesis by the permeable chelators is reversed when chelator is removed. The response to growth factors also differs, with no impermeable chelator inhibition on 10% fetal calf serum contrasting to inhibition by permeable chelators. DNA synthesis with both activation of tyrosine kinase with EGF plus insulin or by thrombin or ceruloplasmin led to protein kinase C activation as inhibited by the impermeable chelators. It is proposed that an iron available on the cell surface is required for DNA synthesis and plasma membrane electron transport.
Alcain
F J
FJ
Department of Molecular Medicine, Karolinska Institute, Stockholm, Sweden.
Löw
H
H
Crane
F L
FL
D000818:Animals; D001059:Apoproteins / Q000494:pharmacology; D002413:Cations, Divalent / Q000494:pharmacology; D002460:Cell Line; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D006224:Cricetinae; D003412:Cricetulus; D004247:DNA / Q000096:biosynthesis*; D004261:DNA Replication / Q000187:drug effects*; D004579:Electron Transport / Q000187:drug effects; D004815:Epidermal Growth Factor / Q000494:pharmacology; D005347:Fibroblasts; D007328:Insulin / Q000494:pharmacology; D007501:Iron / Q000378:metabolism* / Q000494:pharmacology; D007502:Iron Chelating Agents / Q000494:pharmacology*; D007700:Kinetics; D008168:Lung; D010618:Phenanthrolines / Q000494:pharmacology*; D013936:Thymidine / Q000378:metabolism; D014168:Transferrin / Q000494:pharmacology; D014316:Tritium
D001059:Apoproteins; D002413:Cations, Divalent; D007328:Insulin; D007502:Iron Chelating Agents; D010618:Phenanthrolines; D014168:Transferrin; C028284:apotransferrin; D014316:Tritium; C017049:bathophenanthroline disulfonic acid; D004815:Epidermal Growth Factor; D004247:DNA; D007501:Iron; D013936:Thymidine